Droxinavir
Chemical compound
From Wikipedia, the free encyclopedia
Droxinavir (also known as SC 55389A) was an experimental protease inhibitor researched by Pharmacia as a treatment for HIV infection. Its research and development was discontinued on March 06, 1995.[1]
| Names | |
|---|---|
| IUPAC name
3-tert-butyl-1-[(2R,3S)-3-[(2S)-3,3-dimethyl-2-[2-(methylamino)acetamido]butyramido]-2-hydroxy-4-phenylbutyl-1-isopentylurea | |
| Other names
SC 55389A | |
| Identifiers | |
3D model (JSmol) |
|
| ChEMBL | |
| ChemSpider | |
PubChem CID |
|
| UNII | |
CompTox Dashboard (EPA) |
|
| |
| |
| Properties | |
| C29H51N5O4 | |
| Molar mass | 533.75 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
| |
